A generic biopharma company specializing in ophthalmology sought EU expansion but faced challenges with market access, competition, and perception of generics. IQVIA applied MIDAS Disease for disease-specific market analysis, competitor mapping, and patent landscape insights. This enabled identification of gaps in the ophthalmology space, product positioning opportunities, and tailored strategies by country, formulation, and packaging. With a full SWOT analysis and global competitor tracking, the client could align pricing, supply chain, and partnerships with local distributors. The result was improved differentiation, patient-centric product development, and accelerated global footprint in ophthalmology generics.

Join for free to read